Portal de investigación
Mechanisms of Resistance to First-Line Osimertinib in Hispanic Patients With EGFR Mutant Non-Small Cell Lung Cancer (FRESTON-CLICaP)
Autores organización
Autores
- Ruiz-Patiño A
- Recondo G
- Martín C
- Raez L
- Samtani S
- Minata JN
- Blaquier JB
- Enrico D
- Burotto M
- Ordóñez-Reyes C
- Chamorro DF
- Garcia-Robledo JE
- Corrales L
- Zatarain-Barrón ZL
- Más L
- Sotelo C
- Ricaurte L
- Santoyo N
- Cuello M
- Mejía S
- Jaller E
- Vargas C
- Carranza H
- Otero J
- Rodríguez J
- Archila P
- Bermudez M
- Gamez T
- Cordeiro de Lima V
- Freitas H
- Russo A
- Polo C
- Malapelle U
- Perez D.D.M.
- Rolfo C
- Viola L
- Rosell R
- Arrieta O
Grupos de investigación
Resumen
Introduction: Osimertinib is a third generation EGFR-TKI inhibitor approved in the first-line setting for patients with advanced non-small cell lung cancer (NSCLC). Additionally, it represents the treatment of choice in patients who present with T790M mutations and evidence of relapse of the disease. Effectiveness and safety of this drug have been studied in multiple clinical trials and observational studies, however, information regarding outcomes among Hispanic patients treated with Osimertinib is scarce. The objective of this study was to examine real-world effectiveness and safety of first-line Osimertinib in a cohort of Hispanic patients with NSCLC, emphasizing post-progression outcomes. Methods: This is a multicenter, multinational, retrospective cohort study of Hispanic patients treated with Osimertinib as first-line for EGFR-mutated NSCLC. Patients with a confirmed diagnosis of metastatic EGFR-mutated NSCLC who received Osimertinib (80mg/day until evidence of disease progression or presence of intolerable adverse effects) were identified and included. NGS was performed in tumor samples or liquid biopsies among patients who had disease progression. The primary outcome was progression-free survival, and the secondary outcome was post-progression survival. Results: A total of 94 patients from Mexico, Argentina, Costa Rica, Colombia, Panama, Chile and the USA were included, with a median age of 59 years. Identified mutations included EGFR Exon 19 deletions and EGFR pL858R point mutations. Median progression-free survival (PFS) was 14.4 months (95%CI 12.4–18.2 months). Lung/pleura and lymph nodes were the most common sites of progression. Median post-progression survival was 7.73 months (95%CI 4.07 months-Not reached). Factors which negatively affected PFS included presence of liver metastases at diagnosis and a tumor mutational burden > 5 mut/Mb. Conclusion: Treatment with first line osimertinib represents an effective and safe option for Hispanic patients with metastatic NSCLC. Liver metastases and a higher tumor mutation burden were associated with a lower PFS. Despite effectiveness, different mechanisms of resistance were identified among the patients in this cohort, including mutations which can be targeted by other therapeutic options. © 2022
Copyright © 2022. Published by Elsevier Inc.
Datos de la publicación
- ISSN/ISSNe:
- 1525-7304, 1938-0690
- Tipo:
- Article
- Páginas:
- 522-531
- Enlace a otro recurso:
- www.scopus.com
Clinical Lung Cancer Elsevier Inc.
Citas Recibidas en Web of Science: 5
Citas Recibidas en Scopus: 8
Documentos
- No hay documentos
Filiaciones
Keywords
- epidermal growth factor receptor; osimertinib; adult; Argentina; Article; cancer growth; cancer patient; cancer resistance; cancer survival; Chile; cohort analysis; Colombia; controlled study; Costa Rica; drug efficacy; drug safety; exon; female; gene deletion; Hispanic; human; liver metastasis; lung biopsy; lymph node metastasis; major clinical study; male; Mexico; middle aged; non small cell lung cancer; observational study; outcome assessment; Panama; pleura metastasis; point mutation; progression free survival; retrospective study; tumor mutational burden; United States
Proyectos asociados
EFECTO DEL EXTRACTO DE Trametes versicolor SOBRE EL FENOTIPO Y LA FUNCIÓN DE CÉLULAS DENDRÍTICAS HUMANAS CONDICIONADAS CON MEDIOS DE CÉLULAS DE CARCINOMA ORAL
Investigador Principal: ANDRES FELIPE CARDONA MENDOZA
PCI-2019-10805 . 2020
Citar la publicación
Cardona AF,Ruiz A,Recondo G,Martín C,Raez L,Samtani S,Minata JN,Blaquier JB,Enrico D,Burotto M,Ordóñez C,Chamorro DF,Garcia JE,Corrales L,Zatarain ZL,Más L,Sotelo C,Ricaurte L,Santoyo N,Cuello M,Mejía S,Jaller E,Vargas C,Carranza H,Otero J,Rodríguez J,Archila P,Bermudez M,Gamez T,Cordeiro de Lima V,Freitas H,Russo A,Polo C,Malapelle U,Perez DDM,Rolfo C,Viola L,Rosell R,Arrieta O. Mechanisms of Resistance to First-Line Osimertinib in Hispanic Patients With EGFR Mutant Non-Small Cell Lung Cancer (FRESTON-CLICaP). Clin Lung Cancer. 2022. 23. (6):p. 522-531. IF:3,600. (2).